ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Vorsetuzumab

Vorsetuzumab

Request For Quotation
Vorsetuzumab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Vorsetuzumab Basic information
Product Name:Vorsetuzumab
Synonyms:Vorsetuzumab;Research Grade Vorsetuzumab(DHE01902);Vorsetuzumab (anti-CD70);SGN-70;Research Grade Vorsetuzumab
CAS:1165740-62-4
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Vorsetuzumab Structure
Vorsetuzumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Vorsetuzumab Usage And Synthesis
UsesVorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].
in vivo

Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1].

Animal Model:Burkitt’s lymphoma xenograft model in SRG mice[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; every other day; for 12 d
Result:Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).
References[1] Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. DOI:10.1073/pnas.1710877114
Vorsetuzumab Preparation Products And Raw materials
Tag:Vorsetuzumab(1165740-62-4) Related Product Information
Caplacizumab Sifalimumab Daratumumab Clazakizumab Enavatuzumab Motavizumab nimotuzumab Tucotuzumab Celmoleukin Pritumumab Sintilimab